News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diosynth Biotechnology (Research Triangle Park) Announces Agreement with VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) for Process Development and Clinical Production of VGX-100 for the Treatment of Cancer


5/2/2007 12:01:01 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Diosynth Biotechnology announced today that it has signed an agreement with VGX Pharmaceuticals for process development activities and cGMP production of clinical trial material for their biological therapeutic drug candidate VGX-100.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES